7 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
Follow Servier: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma Combination of Lonsurf® and Irinotecan - Cholangiocarcinoma | Phase 2 | Completed | Heinrich-Heine University, Duesseldorf | 28 | 2021-10-28 | 2024-03-27 |
| TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer trifluridine/tipiracil - Breast Neoplasm, Chemotherapy Effect | Phase 2 | Completed | Borstkanker Onderzoek Groep | 52 | 2020-09-25 | 2026-05-22 |
| Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma Onivyde, Paclitaxel - Squamous Cell Carcinoma | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 106 | 2019-03-07 | 2025-01-08 |
| Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma Liposomal Irinotecan, Fluorouracil, Folinic Acid - Oncology, Neuroendocrine Carcinoma | Phase 2 | Completed | The Christie NHS Foundation Trust | 58 | 2018-11-13 | 2024-12-30 |
| Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B) - Adenocarcinoma Metastatic, Biliary Tract Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 93 | 2018-01-24 | 2025-10-01 |
| Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies nal-IRI, 5-FU, leucovorin - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Completed | AIO-Studien-gGmbH | 100 | 2017-10-24 | 2022-05-18 |
| GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma Obinutuzumab and Pixantrone - Lymphoma, Non-Hodgkin | Phase 2 | Completed | Johannes Gutenberg University Mainz | 70 | 2015-08-14 | 2022-03-31 |
Cholangiocarcinoma (2) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Squamous Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1)
Fluorouracil (3) · Leucovorin (3) · irinotecan sucrosofate (3) · Docetaxel (1) · Gemcitabine (1) · Irinotecan (1) · Paclitaxel (1) · obinutuzumab (1) · pixantrone (1) · trifluridine tipiracil drug combination (1)
Germany (4) · France (1) · Netherlands (1) · United Kingdom (1)
A. Elise van Leeuwen-Stok, PhD (1) · Arndt Vogel, Prof. (1) · Christoph Roderburg, Prof. (1) · Georg Hess, MD (1) · Mairead McNamara (1) · Thomas J. Ettrich, Dr. (1)
PMID 31646981, PMID 32029495, PMID 37217885, PMID 37287870, PMID 38843469, PMID 38870977, PMID 40017682, PMID 40147791, PMID 40876084
2016 (2), 2014 (1)